Skip to main content

Table 1 Demographic and baseline characteristics of study populations

From: Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension

Characteristic Pooled data NOH301 [3] NOH302 [6] NOH306
Droxidopa (n = 225) Placebo (n = 235) Droxidopa (n = 82) Placebo (n = 80) Droxidopa (n = 50) Placebo (n = 51) Droxidopa (n = 114) Placebo (n = 108)
Mean (SD) age, y 65.0 (14.7) 65.4 (15.6) 57.4 (16.9) 55.7 (20.0) 63.1 (13.8) 66.6 (11.3) 72.6 (7.5) 72.4 (8.0)
Men, n (%) 132 (58.7) 142 (60.4) 42 (51.2) 42 (52.5) 30 (60.0) 32 (62.7) 77 (67.5) 68 (63.0)
White, n (%) 220 (97.8) 221 (94.0) 82 (100) 75 (93.8) 49 (98.0) 48 (94.1) 110 (96.5) 102 (94.4)
Primary clinical diagnosis, n (%)
 PD 150 (66.7) 157 (66.8) 35 (42.7) 31 (38.8) 21 (42.0) 23 (45.1) 114 (100) 108 (100)
 MSA 31 (13.8) 25 (10.6) 15 (18.3) 11 (13.8) 17 (34.0) 13 (25.5) 0 0
 Pure autonomic failure 34 (15.1) 38 (16.2) 26 (31.7) 28 (35.0) 8 (16.0) 10 (19.6) 0 0
 DBHD 0 1 (0.4) 0 0 0 1 (2.0) 0 0
 NDAN 4 (1.8) 9 (3.8) 2 (2.4) 6 (7.5) 2 (4.0) 3 (5.9) 0 0
 Other 6 (2.7) 5 (2.1) 4 (4.9)a 4 (5.0)b 2 (4.0)c 1 (2.0) c 0 0
OHSA Item 1 score
N 224 236 81 79 50 51 92 105
 Mean (SD) 6.0 (2.2) 5.8 (2.4) 6.5 (2.1) 6.2 (2.4) 6.6 (2.0) 6.3 (2.3) 5.4 (2.1) 5.1 (2.3)
  1. DBHD dopamine β-hydroxylase deficiency, MSA multiple system atrophy, NDAN nondiabetic autonomic neuropathy, OHSA Orthostatic Hypotension Symptom Assessment, PD Parkinson disease
  2. aThree patients diagnosed as “likely pure autonomic failure” and 1 patient diagnosed as “likely MSA”
  3. bDiagnosed as “likely pure autonomic failure”
  4. cAdditional information not available